We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
Read MoreHide Full Article
The Medicines Company incurred first-quarter 2019 adjusted loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents and the year-ago loss of 76 cents.
Shares of The Medicines Company have surged 55.7% so far this year compared with the industry’s increase of 3.3%.
In first-quarter 2019, the Medicines Company did not generate any revenues. The Zacks Consensus Estimate for the metric was pegged at $4.37 million. However, in the prior-year quarter, the company’s revenues had grossed $7.8 million.
The company divested all its marketed products, namely Angiomax, Vabomere, Orbactiv and Minocin in 2018 as part of its restructuring activities to focus solely on developing its late-stage candidate, inclisiran. This explains the absence of revenues in the first quarter.
Adjusted selling, general and administrative expenses (SG&A) were down 27% year over year to $13.1 million in the reported quarter. Adjusted research and development expenses (R&D) declined 32.4% to $26.4 million.
The Medicines Company’s cash and cash equivalents as of Mar 31, 2019 totaled $199.7 million compared with $238.3 million on Dec 31, 2018. The company believes that this existing cash balance will enable it to fund operating expenses through 2020.
Pipeline Update
The Medicines Company has one promising candidate, inclisiran, (hypercholesterolemia) in its pipeline. The company along with partner Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) is evaluating inclisiran in several phase III ORION studies for treating patients with atherosclerotic cardiovascular disease (“ASCVD”) and elevated bad cholesterol (LDL-cholesterol).
Last week, the Independent Data Monitoring Committee (“IDMC”) recommended continuation of ongoing phase III ORION studies on inclisiran as designed. The same is being conducted without any modification.
The latest suggestion from IDMC came after the regulatory body’s sixth review of unblinded safety and efficacy data from ORION programs on the PCSK9 inhibitor, which the Medicines Company considers to have blockbuster potential.
The companies expect to present top-line data from the ORION analyses early in the third quarter of 2019 and subsequently file for a new drug application (NDA) in the United States as well as a marketing authorization application (MAA) in the EU.
The Medicines Company Price, Consensus and EPS Surprise
The Medicines Company currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are Celsion Corporation and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celsion’s loss estimates have narrowed from 94 cents to 78 cents for 2019 and 2020over the past 60 days.
ANI Pharmaceuticals’ earnings per share estimates have moved upward from $5.90 to $5.97 for 2019 and $6.58 to $6.62 for 2020 over the past 60 days.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
The Medicines Company incurred first-quarter 2019 adjusted loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents and the year-ago loss of 76 cents.
Shares of The Medicines Company have surged 55.7% so far this year compared with the industry’s increase of 3.3%.
In first-quarter 2019, the Medicines Company did not generate any revenues. The Zacks Consensus Estimate for the metric was pegged at $4.37 million. However, in the prior-year quarter, the company’s revenues had grossed $7.8 million.
The company divested all its marketed products, namely Angiomax, Vabomere, Orbactiv and Minocin in 2018 as part of its restructuring activities to focus solely on developing its late-stage candidate, inclisiran. This explains the absence of revenues in the first quarter.
Adjusted selling, general and administrative expenses (SG&A) were down 27% year over year to $13.1 million in the reported quarter. Adjusted research and development expenses (R&D) declined 32.4% to $26.4 million.
The Medicines Company’s cash and cash equivalents as of Mar 31, 2019 totaled $199.7 million compared with $238.3 million on Dec 31, 2018. The company believes that this existing cash balance will enable it to fund operating expenses through 2020.
Pipeline Update
The Medicines Company has one promising candidate, inclisiran, (hypercholesterolemia) in its pipeline. The company along with partner Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) is evaluating inclisiran in several phase III ORION studies for treating patients with atherosclerotic cardiovascular disease (“ASCVD”) and elevated bad cholesterol (LDL-cholesterol).
Last week, the Independent Data Monitoring Committee (“IDMC”) recommended continuation of ongoing phase III ORION studies on inclisiran as designed. The same is being conducted without any modification.
The latest suggestion from IDMC came after the regulatory body’s sixth review of unblinded safety and efficacy data from ORION programs on the PCSK9 inhibitor, which the Medicines Company considers to have blockbuster potential.
The companies expect to present top-line data from the ORION analyses early in the third quarter of 2019 and subsequently file for a new drug application (NDA) in the United States as well as a marketing authorization application (MAA) in the EU.
The Medicines Company Price, Consensus and EPS Surprise
The Medicines Company Price, Consensus and EPS Surprise | The Medicines Company Quote
Zacks Rank & Stocks to Consider
The Medicines Company currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are Celsion Corporation and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celsion’s loss estimates have narrowed from 94 cents to 78 cents for 2019 and 2020over the past 60 days.
ANI Pharmaceuticals’ earnings per share estimates have moved upward from $5.90 to $5.97 for 2019 and $6.58 to $6.62 for 2020 over the past 60 days.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>